N (6)-Methyladenosine modification: a novel pharmacological target for anti-cancer drug development

N(6)-甲基腺苷修饰:抗癌药物研发的新型药理学靶点

阅读:2

Abstract

N (6)-Methyladenosine (m(6)A) modification is the most pervasive modification of human mRNA molecules. It is reversible via regulation of m(6)A modification methyltransferase, demethylase and proteins that preferentially recognize m(6)A modification as "writers", "erasers" and "readers", respectively. Altered expression levels of the m(6)A modification key regulators substantially affect their function, leading to significant phenotype changes in the cell and organism. Recent studies have proved that the m(6)A modification plays significant roles in regulation of metabolism, stem cell self-renewal, and metastasis in a variety of human cancers. In this review, we describe the potential roles of m(6)A modification in human cancers and summarize their underlying molecular mechanisms. Moreover, we will highlight potential therapeutic approaches by targeting the key m(6)A modification regulators for cancer drug development.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。